<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: To assess the long-term efficacy and safety of infliximab therapy for the treatment of <z:chebi fb="6" ids="22696">Beh</z:chebi>çet's disease patients with ocular involvement who failed to respond or did not tolerate conventional treatment </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: Retrospective study of 12 patients treated with infliximab at a starting dose of 5 mg/kg </plain></SENT>
<SENT sid="2" pm="."><plain>RESULTS: Infliximab was infused during a mean of 31.43 months </plain></SENT>
<SENT sid="3" pm="."><plain>The mean follow-up period was 35.77 months (range: 6-94) </plain></SENT>
<SENT sid="4" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients achieved remission, 7 of whom did not need any adjuvant immunosuppressive therapy and 9 of whom were able to discontinue systemic <z:chebi fb="0" ids="50858">corticosteroids</z:chebi> </plain></SENT>
<SENT sid="5" pm="."><plain>Visual acuity remained stable or improved in 20/21 eyes </plain></SENT>
<SENT sid="6" pm="."><plain>Ten patients did not report any side effect of the medication or those were mild and tolerable </plain></SENT>
<SENT sid="7" pm="."><plain>We observed two major adverse events requiring withdrawal of infliximab </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS: Infliximab therapy is an effective biologic agent for the treatment of <z:hpo ids='HP_0100533'>ocular inflammation</z:hpo> in <z:chebi fb="6" ids="22696">Beh</z:chebi>çet's disease unresponsive to the standard immunosuppressive therapy </plain></SENT>
</text></document>